Atlas FDA

Predicate Research Report · generated 2026-08-21 · Print / save as PDF · Save to account

Genmark Diagnostics, Incorporated — Predicate Candidate Screening

7 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

178 daysmedian FDA review time
255 days90th percentile
7clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K213236ePlex Blood Culture Identification Gram Negative (BCID-GN) PGenmark Diagnostics, Incorporated2022-04-272090
K182619ePlex Blood Culture Identification Gram Negative (BCID-GN) PGenmark Diagnostics, Incorporated2019-04-122000
K182690ePlex Blood Culture Identification Panel Fungal Pathogen (BCGenmark Diagnostics, Incorporated2018-12-21850
K181663ePlex Blood Culture Identification Panel - Gram Positive (BCGenmark Diagnostics, Incorporated2018-12-201780
K163652ePlex InstrumentGenmark Diagnostics, Incorporated2017-06-091680
K163636ePlex Respiratory Pathogen PanelGenmark Diagnostics, Incorporated2017-06-091690
K152612eSensor Warfarin Sensitivity Saliva TestGenmark Diagnostics, Incorporated2016-05-262550

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda